Personalized neoantigen-based T cell therapy triggers cytotoxic lymphocytes expressing polyclonal TCR against metastatic ovarian cancer.
Hung SI, Chu MT, Hou MM, Lee YS, Yang CK, Chu SY, Liu FY, Hsu HC, Pao SC, Teng YC, Chen CB, Chao A, Chung WH, Chang JW, Lai CH.
Hung SI, et al. Among authors: chu sy.
Biomed Pharmacother. 2023 Dec 31;169:115928. doi: 10.1016/j.biopha.2023.115928. Epub 2023 Nov 26.
Biomed Pharmacother. 2023.
PMID: 38011788
Free article.